ESTRO 2022 - Abstract Book

S361

Abstract book

ESTRO 2022

PD-0417 Planned total duration of triptorelin treatment in patients with prostate cancer, TALISMAN study

G. Crehange 1 , T. Lebret 2 , J. Rigaud 3 , N. Pello-Leprince-Ringuet 4 , A.S. Grandoulier 5 , A. Thiery Vuillemin 6

1 Institut Curie, Radiation Oncology, Paris, France; 2 Hopital Foch, Urology, Suresnes, France; 3 CHU Nantes, Urology, Nantes, France; 4 IPSEN, Medical direction, Boulogne Billancourt, France; 5 IPSEN, Medical Direction, Boulogne Billancourt, France; 6 CHRU Jean Minjoz, Medical Oncology, Besancon, France

Purpose or Objective

Modalities of use of androgen deprivation therapy may depend on tumor aggressiveness, patient frailty and physician habits. Our purpose here was to describe main reasons of planned total duration of triptorelin treatment declared by the physician in real life, according to circumstance of prescription. Materials and Methods Initiated in November 2020, a prospective, multicenter, non-interventional study is ongoing in France (TALISMAN, NCT04593420). Urologists, radiation oncologists and medical oncologists recruited patients with histologically confirmed prostate cancer (PCa), eligible for a ≥ 12-month triptorelin therapy within its label. Decision of initiation of triptorelin treatment was made before inclusion. 786 patients were planned to be enrolled, with a 12-month follow-up. Primary objective is to describe the proportion of patients treated continuously with triptorelin for 12 months after initiation. Interim analysis of baseline data was planned when 50% of patients were enrolled. A descriptive analysis of baseline parameters of subgroups according to circumstance of prescription [high risk localized tumor (HRL), locally advanced tumor (LA), biochemical recurrence (BCR), metastatic stage (MS)] was performed.